Glenmark Pharmaceuticals Limited (BOM:532296)
India
· Delayed Price · Currency is INR 1,381.20
-14.05 (-1.01%)
At close: May 12, 2025
Glenmark Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Net Income | -15,017 | 2,972 | 9,417 | 9,700 | 7,760 | Upgrade
|
| Depreciation & Amortization | 4,792 | 3,810 | 1,613 | 3,162 | 2,710 | Upgrade
|
| Other Amortization | 1,517 | 2,303 | 3,254 | 1,273 | 1,461 | Upgrade
|
| Loss (Gain) From Sale of Assets | -8.26 | -57.25 | 64.64 | -3.54 | -173.81 | Upgrade
|
| Loss (Gain) From Sale of Investments | -7,450 | -0.26 | -149.81 | -0.34 | - | Upgrade
|
| Stock-Based Compensation | 49.62 | 67.74 | 79.16 | 79.37 | 30.84 | Upgrade
|
| Provision & Write-off of Bad Debts | 176.5 | 118.72 | 298.74 | 113.69 | 178.33 | Upgrade
|
| Other Operating Activities | 15,928 | 1,499 | 2,122 | 845.41 | 686.77 | Upgrade
|
| Change in Accounts Receivable | 9,695 | -8,487 | -5,493 | -1,179 | -2,927 | Upgrade
|
| Change in Inventory | -5,139 | -3,752 | -2,034 | -1,338 | 972.56 | Upgrade
|
| Change in Accounts Payable | -7,344 | 1,662 | 847.57 | 1,605 | 1,527 | Upgrade
|
| Change in Other Net Operating Assets | -5,182 | -167.73 | 1,067 | -2,946 | 1,698 | Upgrade
|
| Operating Cash Flow | -2,654 | 6,254 | 11,087 | 11,312 | 13,924 | Upgrade
|
| Operating Cash Flow Growth | - | -43.59% | -1.99% | -18.76% | 5.15% | Upgrade
|
| Capital Expenditures | -8,984 | -6,078 | -7,901 | -7,748 | -9,314 | Upgrade
|
| Sale of Property, Plant & Equipment | 20.8 | 572.29 | 15.8 | 994.33 | 1,560 | Upgrade
|
| Divestitures | 54,496 | - | - | - | - | Upgrade
|
| Investment in Securities | - | -10.08 | -100.18 | - | 50 | Upgrade
|
| Other Investing Activities | 75.82 | 230.51 | 4,653 | 0.89 | -131.75 | Upgrade
|
| Investing Cash Flow | 45,609 | -5,285 | -3,333 | -6,752 | -7,835 | Upgrade
|
| Short-Term Debt Issued | 4,811 | - | - | 855.71 | 1,231 | Upgrade
|
| Long-Term Debt Issued | - | 11,632 | 21,301 | 16,443 | 7,220 | Upgrade
|
| Total Debt Issued | 4,811 | 11,632 | 21,301 | 17,299 | 8,451 | Upgrade
|
| Short-Term Debt Repaid | - | -200 | -1,417 | - | - | Upgrade
|
| Long-Term Debt Repaid | -37,539 | -6,198 | -31,201 | -18,076 | -9,197 | Upgrade
|
| Total Debt Repaid | -37,539 | -6,398 | -32,618 | -18,076 | -9,197 | Upgrade
|
| Net Debt Issued (Repaid) | -32,728 | 5,234 | -11,317 | -777.1 | -746.55 | Upgrade
|
| Issuance of Common Stock | 12 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -704.52 | -703.86 | -926.95 | -704.47 | -685.54 | Upgrade
|
| Other Financing Activities | -5,641 | -5,305 | 7,040 | -2,936 | -3,015 | Upgrade
|
| Financing Cash Flow | -39,061 | -774.56 | -5,205 | -4,418 | -4,447 | Upgrade
|
| Foreign Exchange Rate Adjustments | 176.79 | 123.87 | 175.5 | 136.22 | 97.64 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -1,918 | 6.68 | - | - | - | Upgrade
|
| Net Cash Flow | 2,152 | 325 | 2,724 | 278.2 | 1,740 | Upgrade
|
| Free Cash Flow | -11,638 | 176.29 | 3,185 | 3,565 | 4,610 | Upgrade
|
| Free Cash Flow Growth | - | -94.47% | -10.64% | -22.68% | 429.93% | Upgrade
|
| Free Cash Flow Margin | -9.20% | 0.15% | 2.59% | 3.26% | 4.33% | Upgrade
|
| Free Cash Flow Per Share | -41.24 | 0.63 | 11.29 | 12.63 | 16.34 | Upgrade
|
| Cash Interest Paid | 5,168 | 3,115 | 2,505 | 2,936 | 3,015 | Upgrade
|
| Cash Income Tax Paid | 10,475 | 6,405 | 5,584 | 5,102 | 4,670 | Upgrade
|
| Levered Free Cash Flow | 43,246 | -11,604 | 1,853 | 1,154 | 1,392 | Upgrade
|
| Unlevered Free Cash Flow | 46,471 | -9,423 | 3,716 | 3,361 | 3,750 | Upgrade
|
| Change in Net Working Capital | -40,061 | 16,639 | 4,830 | 4,132 | -746.74 | Upgrade
|
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.